At Rubedo Life Sciences, we developed a novel concept of intelligent discovery platform  combined with recombinant chemistry to selectively target specific cell types of the body, without toxicity or side effects.

The first product line developed by Rubedo labs is based on smart molecules that can target a population of pro-inflammatory cells that accumulate in the body with age, called “Senescent Cells”. These cells cause increased chronic inflammation, pain, and tissue decay that contribute to age-related diseases like Diabetes, Alzheimer’s, Cardio-Vascular Diseases and Cancer.

By selectively clearing the body of these cells, while preserving adjacent healthy cells, the tissues start to rejuvenate and diseases revert to improved healthy states.


The first of our therapeutic approaches is designed to target these senescent cells (which are normally locked in their cell cycle state called G0) by inducing them to die through a mechanism called apoptosis. By doing so, the body will be specifically cleared of these senescent cells without affecting the other healthy cells present in our bodies.

The consequence of this are rejuvenative effects that restores health.

Our initial indications are:


As a result of any chemotherapy treatment, tissues in the body accumulate a vast amount of senescent cells. As a result, the pro-inflammatory environment promotes tissue decay and the toxicity resulting from chemotherapy worsen its side effects. Patients struggle with longer recovery and higher morbidity following the chemotherapy. Rubedo Life Sciences is developing small molecules that can clear from the body senescent cells accumulated during the chemotherapy, offering improved efficacy, reduced toxicities and less side effects. As a result, patients will experience more efficacy in cancer treatments, improved recovery and a better quality of life.


Frailty is a common geriatric syndrome that embodies an elevated risk of catastrophic declines in health and function among older adults. Frailty is a condition associated with aging, that it has been recognized for centuries. Rubedo Life Sciences is developing small molecules that target age associated senescent cells. These cells, accumulated during aging in every tissue of the body, are at the base of a chronic inflammation which leads to tissue decay, contributing to Frailty Syndrome. By clearing progressively and systematically senescent cells in the elder population, we intend to prevent the onset of Frailty Syndrome and reverse its effects in people already suffering from it, restoring a healthy and youthful quality of life.


Other pipelines in the discovery phase focus on targeting other cell types other than senescence cells, such as stem cells to activate their regenerative potential, progressively lost with age and diseases.

Silicon Valley, CA, USA

Copyright 2020 by Rubedo Life Sciences, inc